Department of Production Animal Medicine, Faculty of Veterinary Medicine, University of Helsinki, Paroninkuja 20, FI-04920 Saarentaus, Finland.
J Dairy Sci. 2010 May;93(5):1960-9. doi: 10.3168/jds.2009-2462.
The efficacy of the combination of systemic enrofloxacin (5mg/kg twice with a 24-h interval, first dose i.v., second dose s.c.) and the nonsteroidal antiinflammatory agent ketoprofen (3mg/kg i.m. or 4 mg/kg per os daily for 1 to 3 d) treatment was compared with antiinflammatory treatment only in dairy cows with naturally occurring acute clinical Escherichia coli mastitis. A total of 132 cows with acute clinical mastitis and with confirmed growth of E. coli in a pretreatment milk sample were randomly allocated to 1 of 2 treatment groups. Response to treatment was evaluated clinically and by bacteriological culturing and determination of N-acetyl-beta-d-glucosaminidase (NAGase) activity on d 2 and 21 posttreatment. Enrofloxacin treatment did not increase bacteriological (90.5% of treated vs. 86.8% of nontreated cured) or clinical cure (46.7% of treated vs. 57.1% of nontreated cured), cow survival (95.3% of treated vs. 92.7% of nontreated), or quarter milk production assessed 21 d posttreatment (21.8 vs. 29.3% return to preinfection level for nontreated cows), nor did it decrease mammary gland tissue damage estimated using determination of milk NAGase activity (24.0+/-0.3 vs. 18.3+/-1.3 pmol of 4-methylumbelliferone per min per microL for nontreated cows). Treatment did not influence the number of study cows remaining in the herd after 6 mo (71.9% of treated vs. 80.6% of nontreated). The only significant effects of enrofloxacin were enhancing the bacteriological cure (odds ratio=3.32 for treated cows) and decreasing the clinical cure (odds ratio=0.05 for treated cows) on d 2 posttreatment. Our results did not support the use of enrofloxacin to treat acute clinical E. coli mastitis.
将全身用恩诺沙星（5mg/kg 两次，间隔 24 小时，首剂静脉注射，第二剂皮下注射）和非甾体类抗炎药酮洛芬（3mg/kg 肌肉注射或 4mg/kg 口服，每天 1 至 3 天）联合治疗与仅用抗炎药治疗的效果进行了比较，用于治疗自然发生的急性临床大肠杆菌乳腺炎的奶牛。共有 132 头患有急性临床乳腺炎且预处理奶样中确认有大肠杆菌生长的奶牛被随机分配到 2 个治疗组中的 1 个。在治疗后第 2 天和第 21 天通过临床和细菌培养以及测定 N-乙酰-β-D-氨基葡萄糖苷酶（NAGase）活性来评估治疗反应。恩诺沙星治疗并未增加细菌学（90.5%的治疗组治愈与 86.8%的未治疗组治愈）或临床治愈（46.7%的治疗组与 57.1%的未治疗组治愈）、牛的存活率（95.3%的治疗组与 92.7%的未治疗组），或治疗后 21 天评估的 quarters 牛奶产量（未治疗组的牛奶产量恢复到感染前水平的 21.8%与 29.3%），也未减少使用测定牛奶 NAGase 活性来估计的乳腺组织损伤（24.0+/-0.3 与未治疗组的 18.3+/-1.3 pmol 4-甲基伞形酮/分钟/微升）。治疗并未影响治疗后 6 个月留在牛群中的奶牛数量（71.9%的治疗组与 80.6%的未治疗组）。恩诺沙星唯一的显著影响是在治疗后第 2 天提高了细菌学治愈率（治疗牛的优势比=3.32）和降低了临床治愈率（治疗牛的优势比=0.05）。我们的结果不支持使用恩诺沙星治疗急性临床大肠杆菌乳腺炎。
